BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 23686769)

  • 1. Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer.
    Ma T; Galimberti F; Erkmen CP; Memoli V; Chinyengetere F; Sempere L; Beumer JH; Anyang BN; Nugent W; Johnstone D; Tsongalis GJ; Kurie JM; Li H; Direnzo J; Guo Y; Freemantle SJ; Dragnev KH; Dmitrovsky E
    Mol Cancer Ther; 2013 Aug; 12(8):1545-55. PubMed ID: 23686769
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.
    LaBonte MJ; Wilson PM; Fazzone W; Groshen S; Lenz HJ; Ladner RD
    BMC Med Genomics; 2009 Nov; 2():67. PubMed ID: 19948057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells.
    Zhou Q; Dalgard CL; Wynder C; Doughty ML
    BMC Neurosci; 2011 May; 12():50. PubMed ID: 21615950
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
    Tula-Sanchez AA; Havas AP; Alonge PJ; Klein ME; Doctor SR; Pinkston W; Glinsmann-Gibson BJ; Rimsza LM; Smith CL
    Cancer Biol Ther; 2013 Oct; 14(10):949-61. PubMed ID: 23982416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Negative effect of cyclin D1 overexpression on recurrence-free survival in stage II-IIIA lung adenocarcinoma and its expression modulation by vorinostat in vitro.
    Lee E; Jin D; Lee BB; Kim Y; Han J; Shim YM; Kim DH
    BMC Cancer; 2015 Dec; 15():982. PubMed ID: 26681199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vorinostat, an HDAC inhibitor attenuates epidermoid squamous cell carcinoma growth by dampening mTOR signaling pathway in a human xenograft murine model.
    Kurundkar D; Srivastava RK; Chaudhary SC; Ballestas ME; Kopelovich L; Elmets CA; Athar M
    Toxicol Appl Pharmacol; 2013 Jan; 266(2):233-44. PubMed ID: 23147569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat.
    Carbone C; Di Gennaro E; Piro G; Milone MR; Pucci B; Caraglia M; Budillon A
    Amino Acids; 2017 Mar; 49(3):517-528. PubMed ID: 27761756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vorinostat enhances the cisplatin-mediated anticancer effects in small cell lung cancer cells.
    Pan CH; Chang YF; Lee MS; Wen BC; Ko JC; Liang SK; Liang MC
    BMC Cancer; 2016 Nov; 16(1):857. PubMed ID: 27821078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.
    Lee JH; Choy ML; Ngo L; Foster SS; Marks PA
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14639-44. PubMed ID: 20679231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models.
    Morelli MP; Tentler JJ; Kulikowski GN; Tan AC; Bradshaw-Pierce EL; Pitts TM; Brown AM; Nallapareddy S; Arcaroli JJ; Serkova NJ; Hidalgo M; Ciardiello F; Eckhardt SG
    Clin Cancer Res; 2012 Feb; 18(4):1051-62. PubMed ID: 22173548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.
    Wilson PM; Labonte MJ; Martin SC; Kuwahara ST; El-Khoueiry A; Lenz HJ; Ladner RD
    Invest New Drugs; 2013 Aug; 31(4):845-57. PubMed ID: 23299388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rosmarinic Acid, a Component of Rosemary Tea, Induced the Cell Cycle Arrest and Apoptosis through Modulation of HDAC2 Expression in Prostate Cancer Cell Lines.
    Jang YG; Hwang KA; Choi KC
    Nutrients; 2018 Nov; 10(11):. PubMed ID: 30453545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma.
    Newbold A; Salmon JM; Martin BP; Stanley K; Johnstone RW
    Oncogene; 2014 Nov; 33(47):5415-23. PubMed ID: 24292681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway.
    Sarfstein R; Bruchim I; Fishman A; Werner H
    PLoS One; 2011; 6(9):e24468. PubMed ID: 21931726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma.
    Bensaid D; Blondy T; Deshayes S; Dehame V; Bertrand P; Grégoire M; Errami M; Blanquart C
    Clin Epigenetics; 2018; 10():79. PubMed ID: 29946373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models.
    Dragnev KH; Ma T; Cyrus J; Galimberti F; Memoli V; Busch AM; Tsongalis GJ; Seltzer M; Johnstone D; Erkmen CP; Nugent W; Rigas JR; Liu X; Freemantle SJ; Kurie JM; Waxman S; Dmitrovsky E
    Cancer Prev Res (Phila); 2011 Jun; 4(6):818-28. PubMed ID: 21636548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
    Kretzner L; Scuto A; Dino PM; Kowolik CM; Wu J; Ventura P; Jove R; Forman SJ; Yen Y; Kirschbaum MH
    Cancer Res; 2011 Jun; 71(11):3912-20. PubMed ID: 21502403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
    Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
    Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel suberoylanilide hydroxamic acid histone deacetylase inhibitor derivative, N25, exhibiting improved antitumor activity in both human U251 and H460 cells.
    Zhang S; Huang WB; Wu L; Wang LY; Ye LB; Feng BH
    Asian Pac J Cancer Prev; 2014; 15(10):4331-8. PubMed ID: 24935393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.